Entheon Biomedical Corp. ENTBF
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.70% | -34.31% | -12.04% | -3.21% | -7.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.70% | -34.31% | -12.04% | -3.21% | -7.00% |
| Operating Income | 11.70% | 34.31% | 12.04% | 3.21% | 7.00% |
| Income Before Tax | 112.56% | 28.08% | 1.42% | -7.96% | -2.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 112.56% | 28.08% | 1.42% | -7.96% | -2.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 112.56% | 28.08% | 1.42% | -7.96% | -2.76% |
| EBIT | 11.70% | 34.31% | 12.04% | 3.21% | 7.00% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 116.60% | 57.62% | 42.77% | 36.04% | 39.75% |
| Normalized Basic EPS | 40.67% | 57.98% | 43.30% | 39.73% | 41.86% |
| EPS Diluted | 116.60% | 57.62% | 42.77% | 36.04% | 43.95% |
| Normalized Diluted EPS | 40.67% | 57.98% | 43.30% | 39.73% | 41.86% |
| Average Basic Shares Outstanding | 42.64% | 67.81% | 73.25% | 73.57% | 74.05% |
| Average Diluted Shares Outstanding | 42.64% | 67.81% | 73.25% | 73.57% | 74.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |